Gilead

Wales experts back HIV prophlyaxis, ahead of key meetings

https://pharmaphorum.com/news/wales-experts-back-truvada/

Is BMS the next pharma takeover target?

https://pharmaphorum.com/news/bms-next-pharma-takeover-target/

Gilead aims to challenge GSK’s HIV drug Tivicay

https://pharmaphorum.com/top-pharmaceutical-companies/gilead/gilead-looking-challenge-gsk-hiv-drug-tivicay/

New Gilead and AbbVie hepatitis C combos filed in EU

https://pharmaphorum.com/news/new-gilead-abbvie-hepatitis-c-combos-filed-eu/

Gilead poaches Novartis’ Riva to lead cancer R&D

https://pharmaphorum.com/news/gilead-hires-novartis-oncology-specialist-riva/

Gilead ordered to pay Merck & Co $2.54 bn by US court

https://pharmaphorum.com/news/gilead-ordered-pay-merck-co-2-54-bn-us-court/

NHS England confirms HIV prevention funding – but only via clinical trial

https://pharmaphorum.com/news/nhs-england-extend-hiv-prevention-programme/

UK court victory for access to HIV prevention drug

https://pharmaphorum.com/news/nhs-make-decision-gilead-hiv-prevention-drug/

Gilead’s slump continues, Shire disappoints

https://pharmaphorum.com/news/gileads-slump-continues-shire-disappoints/

1 2 3

Close in 10 seconds

Pharmaphorum.com

Search